Switch theme
Sign up to access all valuation multiples
Siegfried is a global contract development and manufacturing organization. It derives its revenue primarily from long-term supply agreements with biotechnology and pharmaceutical customers. Siegfried develops and manufactures active pharmaceutical ingredients, finished dosage forms (tablets, capsules, sterile vials, ampules, cartridges, and ointments), and viral vectors. The company provides these services throughout the entire drug lifecycle, including chemical and analytical development, pilot manufacturing, and commercial-scale manufacturing. Siegfried has a large global footprint with 13 production sites on three continents.
1873
3.7K+
LTM Revenue $1.6B
LTM EBITDA $354M
$5.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Siegfried has a last 12-month revenue (LTM) of $1.6B and a last 12-month EBITDA of $354M.
In the most recent fiscal year, Siegfried achieved revenue of $1.6B and an EBITDA of $348M.
Siegfried expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Siegfried valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.6B | XXX | $1.6B | XXX | XXX | XXX |
| Gross Profit | $406M | XXX | $395M | XXX | XXX | XXX |
| Gross Margin | 25% | XXX | 25% | XXX | XXX | XXX |
| EBITDA | $354M | XXX | $348M | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | 22% | XXX | XXX | XXX |
| EBIT | $247M | XXX | $239M | XXX | XXX | XXX |
| EBIT Margin | 16% | XXX | 15% | XXX | XXX | XXX |
| Net Profit | $196M | XXX | $192M | XXX | XXX | XXX |
| Net Margin | 12% | XXX | 12% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Siegfried's stock price is CHF 97 (or $116).
Siegfried has current market cap of CHF 4.2B (or $5.1B), and EV of CHF 4.2B (or $5.0B).
See Siegfried trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.0B | $5.1B | XXX | XXX | XXX | XXX | $4.50 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Siegfried has market cap of $5.1B and EV of $5.0B.
Siegfried's trades at 3.2x EV/Revenue multiple, and 14.5x EV/EBITDA.
Equity research analysts estimate Siegfried's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Siegfried has a P/E ratio of 25.9x.
See valuation multiples for Siegfried and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $5.1B | XXX | $5.1B | XXX | XXX | XXX |
| EV (current) | $5.0B | XXX | $5.0B | XXX | XXX | XXX |
| EV/Revenue | 3.2x | XXX | 3.2x | XXX | XXX | XXX |
| EV/EBITDA | 14.2x | XXX | 14.5x | XXX | XXX | XXX |
| EV/EBIT | 20.3x | XXX | 21.0x | XXX | XXX | XXX |
| EV/Gross Profit | 12.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | 25.9x | XXX | 26.4x | XXX | XXX | XXX |
| EV/FCF | 109.6x | XXX | -347.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSiegfried's last 12 month revenue growth is 7%
Siegfried's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $42K for the same period.
Siegfried's rule of 40 is 26% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Siegfried's rule of X is 39% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Siegfried and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | 22% | XXX | XXX | XXX |
| EBITDA Growth | 9% | XXX | 13% | XXX | XXX | XXX |
| Rule of 40 | 26% | XXX | 29% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 39% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $42K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 1% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 3% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 10% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cohance Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Siegfried acquired XXX companies to date.
Last acquisition by Siegfried was XXXXXXXX, XXXXX XXXXX XXXXXX . Siegfried acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Siegfried founded? | Siegfried was founded in 1873. |
| Where is Siegfried headquartered? | Siegfried is headquartered in Switzerland. |
| How many employees does Siegfried have? | As of today, Siegfried has 3.7K+ employees. |
| Is Siegfried publicy listed? | Yes, Siegfried is a public company listed on SWX. |
| What is the stock symbol of Siegfried? | Siegfried trades under SFZN ticker. |
| When did Siegfried go public? | Siegfried went public in 1973. |
| Who are competitors of Siegfried? | Similar companies to Siegfried include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of Siegfried? | Siegfried's current market cap is $5.1B |
| What is the current revenue of Siegfried? | Siegfried's last 12 months revenue is $1.6B. |
| What is the current revenue growth of Siegfried? | Siegfried revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of Siegfried? | Current revenue multiple of Siegfried is 3.2x. |
| Is Siegfried profitable? | Yes, Siegfried is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Siegfried? | Siegfried's last 12 months EBITDA is $354M. |
| What is Siegfried's EBITDA margin? | Siegfried's last 12 months EBITDA margin is 22%. |
| What is the current EV/EBITDA multiple of Siegfried? | Current EBITDA multiple of Siegfried is 14.2x. |
| What is the current FCF of Siegfried? | Siegfried's last 12 months FCF is $45.9M. |
| What is Siegfried's FCF margin? | Siegfried's last 12 months FCF margin is 3%. |
| What is the current EV/FCF multiple of Siegfried? | Current FCF multiple of Siegfried is 109.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
